Company Description
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally.
The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML).
In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML.
It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021.
HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
| Country | Hong Kong |
| Founded | 2000 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,811 |
| CEO | Wei-Guo Su |
Contact Details
Address: Cheung Kong Center, 48th floor Hong Kong Hong Kong | |
| Phone | 852 2121 8200 |
| Website | hutch-med.com |
Stock Details
| Ticker Symbol | HCM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001648257 |
| CUSIP Number | 44842L103 |
| ISIN Number | US44842L1035 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Wei-Guo Su B.Sc., Ph.D. | Chief Executive Officer, Chief Scientific Officer and Executive Director |
| Chig Fung Cheng BEc, CA | Chief Financial Officer and Executive Director |
| Edith Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.E | Company Secretary and Non-Executive Director |
| Yiling Cui | Executive Vice President and Head of Operations |
| David Ng | Head of Investor Relations and Capital Strategies |
| Charles George Rupert Nixon | Group General Counsel |
| Kin Hung Lee M.B.A. | Senior Vice President of Corporate Management and Communications |
| Selina Zhang | Senior Vice President of Global Human Resources |
| Dr. Qingmei Wang Ph.D. | Executive Vice President of Business Development and Strategic Alliances |
| Dr. Zhenping Wu M.B.A, Ph.D. | Executive Vice President of Pharmaceutical Science and Manufacturing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2025 | 6-K | Report of foreign issuer |
| Apr 22, 2025 | 6-K | Report of foreign issuer |
| Apr 7, 2025 | 6-K | Report of foreign issuer |
| Mar 31, 2025 | 6-K | Report of foreign issuer |
| Mar 21, 2025 | 6-K | Report of foreign issuer |
| Mar 20, 2025 | 6-K | Report of foreign issuer |
| Mar 19, 2025 | 6-K | Report of foreign issuer |
| Mar 19, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 19, 2025 | 6-K | Report of foreign issuer |
| Mar 14, 2025 | 6-K | Report of foreign issuer |